85. Idiopathic interstitial pneumonia
514 clinical trials,   377 drugs   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways

Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-004058-32-GB
(EUCTR)
19/12/201412/06/2015Treating pulmonary fibrosis with co-trimoxazoleThe Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-trimoxazole (EME-TIPAC) - Treating pulmonary fibrosis with co-trimoxazole Idiopathic Pulmonary Fibrosis
MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Cotrimoxazole
Product Name: Cotrimoxazole
Product Code: NA
INN or Proposed INN: trimethoprim
Other descriptive name: none
INN or Proposed INN: sulphamethoxazole
Other descriptive name: none
Norfolk and Norwich University Hospital NHS Foundation TrustNULLNot RecruitingFemale: yes
Male: yes
330Phase 3United Kingdom
2NCT01777737
(ClinicalTrials.gov)
November 25, 201325/1/2013Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With CotrimoxazolePilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Cotrimoxazole;Drug: PlaceboFundación Pública Andaluza para la gestión de la Investigación en SevillaJunta de AndaluciaTerminated18 Years80 YearsAll3Phase 3Spain
3EUCTR2012-005409-38-ES
(EUCTR)
19/04/201329/01/2013First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole.Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis.
MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Parasitic Diseases [C03]
Trade Name: SEPTRIN
INN or Proposed INN: TRIMETHOPRIM
Other descriptive name: TRIMETHOPRIM
INN or Proposed INN: SULFAMETHOXAZOLE
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)NULLNot RecruitingFemale: yes
Male: yes
56Phase 3Spain